Adult Asthma #2 - CPL | US
Offer Details: | |
|---|---|
| Offer Name: | Adult Asthma #2 - CPL | US |
| Payout: | $25.00 / CPA |
| Preview: | Preview Landing Page |
| Categories: | Clinical Trials |
| Network: | DYNU IN MEDIA |
| Last Updated: | Jun 25, 2025 |
| Countries: | US |
Ages: 18+
Gender: Any
Study Description:
The purpose of this clinical study is to test if the use of an approved asthma medication, dupilumab, can preserve long term lung function in people with moderate to severe asthma. If you are eligible, you will be asked to attend a screening visit to determine if you can enroll in the study. If enrolled, you will receive either dupilumab or placebo to be given as an injection once every 2 weeks for 3 years. You will have a 2:1 chance of being assigned dupilumab versus the placebo. The study medication will be given alongside current standard of care asthma therapy. Your total participation will last approximately 3 years and 4 months and you will be asked to attend 15 doctor’s visits. During these visits, you will complete various diagnostic and laboratory tests. The doctor’s office conducting the study will be able to provide you with more information about the study requirements. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated for time and travel.
Medical indications: Asthma
Exclusionary indications: COPD, Emphysema, Pulmonary Fibrosis, Cystic Fibrosis
Amount of visits: 15
Length of the study: Approximately 3 years and 4 months
Medication type: Injectable
Doses: Injection once every 2 weeks for 3 years
Compensation: No compensation provided
PROOF REQUIRED
Qualifications:
- Must be diagnosed with asthma 1 year or longer
- Must use daily inhaler that contains a corticosteroid
Highest DQs:
- In the past year, have had an asthma exacerbation (a worsening of symptoms) that required: Treatment with systemic (oral, IV, injectable) corticosteroids for at least 3 days or Led to an emergency room/urgent care visit or hospitalization?
- Cannot have a history of any of the following lung conditions: COPD, Bronchiectasis, Cystic Fibrosis, Sarcoidosis, or Emphysema
- Must be a former smoker (of over 6 months) or have never smoked (includes vapes and marijuana)
- Cannot have smoked a pack of cigarettes per day or more for 10 or more years
Gender: Any
Study Description:
The purpose of this clinical study is to test if the use of an approved asthma medication, dupilumab, can preserve long term lung function in people with moderate to severe asthma. If you are eligible, you will be asked to attend a screening visit to determine if you can enroll in the study. If enrolled, you will receive either dupilumab or placebo to be given as an injection once every 2 weeks for 3 years. You will have a 2:1 chance of being assigned dupilumab versus the placebo. The study medication will be given alongside current standard of care asthma therapy. Your total participation will last approximately 3 years and 4 months and you will be asked to attend 15 doctor’s visits. During these visits, you will complete various diagnostic and laboratory tests. The doctor’s office conducting the study will be able to provide you with more information about the study requirements. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated for time and travel.
Medical indications: Asthma
Exclusionary indications: COPD, Emphysema, Pulmonary Fibrosis, Cystic Fibrosis
Amount of visits: 15
Length of the study: Approximately 3 years and 4 months
Medication type: Injectable
Doses: Injection once every 2 weeks for 3 years
Compensation: No compensation provided
PROOF REQUIRED
Qualifications:
- Must be diagnosed with asthma 1 year or longer
- Must use daily inhaler that contains a corticosteroid
Highest DQs:
- In the past year, have had an asthma exacerbation (a worsening of symptoms) that required: Treatment with systemic (oral, IV, injectable) corticosteroids for at least 3 days or Led to an emergency room/urgent care visit or hospitalization?
- Cannot have a history of any of the following lung conditions: COPD, Bronchiectasis, Cystic Fibrosis, Sarcoidosis, or Emphysema
- Must be a former smoker (of over 6 months) or have never smoked (includes vapes and marijuana)
- Cannot have smoked a pack of cigarettes per day or more for 10 or more years
DYNU IN MEDIA
DYNU IN MEDIA is a super match CPA/CPL network for earning money online that provides you with all techniques allowing you to monetize your traffic in all channels. We guarantee outstanding support to our publishers. Our devoted team with experience in the affiliate marketing industry will give you full-assist, direct offers in a wide-ranging variety of verticals and top GEOs, and a flexible payment schedule of NET15 & NET30. Hitting more than 20,000 leads generated daily for over 200 influential clients, along with an increasing number of HQ publishers to 300 and more, DYNU IN MEDIA is taking high pride in our professionalism and high integrity.
